Cargando…
Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
BACKGROUND: Multi-drug resistance (MDR) remains a significant obstacle to successful chemotherapy treatment for osteosarcoma patients. One of the central causes of MDR is the overexpression of the membrane bound drug transporter protein P-glycoprotein (P-gp), which is the protein product of the MDR...
Autores principales: | Liu, Tang, Li, Zhihong, Zhang, Qing, Bernstein, Karen De Amorim, Lozano-Calderon, Santiago, Choy, Edwin, Hornicek, Francis J., Duan, Zhenfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347784/ https://www.ncbi.nlm.nih.gov/pubmed/27835872 http://dx.doi.org/10.18632/oncotarget.13148 |
Ejemplares similares
-
Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2010) -
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017) -
miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016) -
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014) -
MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
por: Yang, Xiaoqian, et al.
Publicado: (2015)